Predicted protein targets (top 3)
| gene | UniProt | supporting neighbours | confidence | |
|---|---|---|---|---|
| ▸ | HDAC1 | Q13547 | 1/20 | 0.30 |
| ▸ | HDAC2 | Q92769 | 1/20 | 0.30 |
| ▸ | HDAC6 | Q9UBN7 | 1/20 | 0.30 |
Click a target to see other patent compounds predicted against it — the reverse direction, in place.
Similar compounds — the chemically nearest patent molecules
Nearest neighbours by Morgan-fingerprint cosine across the patent-compound collection, with each neighbour's top predicted target and the predicted targets it shares with this molecule.
| Compound | similarity | top predicted | shared targets | |
|---|---|---|---|---|
| SCHEMBL2767871 | 1.00 | HDAC1 (0.30) | HDAC1HDAC2HDAC6 | |
| SCHEMBL3928699 | 0.78 | HDAC1 (0.30) | HDAC1HDAC2HDAC6 | |
| SCHEMBL24671528 | 0.75 | — | — | |
| SCHEMBL8189934 | 0.75 | HDAC6 (0.32) | HDAC1HDAC2HDAC6 | |
| SCHEMBL8189932 | 0.75 | HDAC6 (0.32) | HDAC1HDAC2HDAC6 | |
| SCHEMBL20355490 | 0.75 | HDAC6 (0.32) | HDAC1HDAC2HDAC6 | |
| SCHEMBL8737769 | 0.75 | HDAC6 (0.39) | HDAC1HDAC2HDAC6 | |
| SCHEMBL16808277 | 0.73 | CA12 (0.30) | — | |
| SCHEMBL7038864 | 0.73 | CA12 (0.30) | — | |
| SCHEMBL3295359 | 0.72 | HDAC6 (0.33) | HDAC1HDAC2HDAC6 |
Similarity is cosine over the 2,048-bit Morgan fingerprint (≈ Tanimoto). Identical fingerprints score 1.00.
Patent provenance — the patents this molecule appears in, and who filed them
Claimed or disclosed in 17 patents. claimed = in the patent's claims; disclosed = body only.
| Patent | Title | Assignee | Published | Priority | Filing | Country | Status |
|---|---|---|---|---|---|---|---|
| US-20190055283-A1 | AZA-PEPTIDE ALDEHYDES AND KETONES | OHIO STATE INNOVATION FOUNDATION | 2019-02-21 | — | — | US | disclosed |
| EP-3423468-A1 | AZA-PEPTIDE ALDEHYDES AND KETONES | The Ohio State Innovation Foundation (US) | 2019-01-09 | — | — | EP | disclosed |
| US-9872495-B2 | Peptoid oligomers, pharmaceutical compositions and methods of using the same | NEW YORK UNIVERSITY (US) | 2018-01-23 | — | — | US | disclosed |
| EP-3240775-A2 | ANTIMICROBIAL COMPOUNDS, COMPOSITIONS AND METHODS | Swansea University (GB) | 2017-11-08 | — | — | EP | disclosed |
| US-20160219880-A1 | PEPTOID OLIGOMERS, PHARMACEUTICAL COMPOSITIONS AND METHODS OF USING THE SAME | NEW YORK UNIVERSITY | 2016-08-04 | — | — | US | disclosed |
| WO-2016108045-A2 | ANTIMICROBIAL COMPOUNDS, COMPOSITIONS AND METHODS | SWANSEA UNIVERSITY (GB) | 2016-07-07 | — | — | WO | disclosed |
| US-9315548-B2 | Peptoid oligomers, pharmaceutical compositions and methods of using the same | NEW YORK UNIVERSITY (US) | 2016-04-19 | — | — | US | disclosed |
| US-20150011465-A1 | PEPTOID OLIGOMERS, PHARMACEUTICAL COMPOSITIONS AND METHODS OF USING THE SAME | NEW YORK UNIVERSITY | 2015-01-08 | — | — | US | disclosed |
| US-8828413-B2 | Peptoid oligomers, pharmaceutical compositions and methods of using the same | NEW YORK UNIVERSITY (US) | 2014-09-09 | — | — | US | disclosed |
| US-8268855-B2 | 1,6-dihydro-1,3,5,6-tetraaza-as-indacene based tricyclic compounds and pharmaceutical compositions comprising same | BRISTOL-MYERS SQUIBB COMPANY (US) | 2012-09-18 | — | — | US | disclosed |
| US-20100222255-A1 | PEPTOID OLIGOMERS, PHARMACEUTICAL COMPOSITIONS AND METHODS OF USING THE SAME | NEW YORK UNIVERSITY | 2010-09-02 | — | — | US | disclosed |
| US-20100210629-A1 | 1,6-DIHYDRO-1,3,5,6-TETRAAZA-AS-INDACENE BASED TRICYCLIC COMPOUNDS AND PHARMACEUTICAL COMPOSITIONS COMPRISING SAME | BRISTOL-MYERS SQUIBB COMPANY | 2010-08-19 | — | — | US | disclosed |
| US-7737279-B2 | 1,6-dihydro-1,3,5,6-tetraaza-as-indacene based tricyclic compounds and pharmaceutical compositions comprising same | BRISTOL-MYERS SQUIBB COMPANY (US) | 2010-06-15 | — | — | US | disclosed |
| EP-1888584-B1 | 1, 6 -DIHYDRO- 1,3, 5, 6-TETRAAZA-AS-INDACENE BASED TRICYCLIC COMPOUNDS AND PHARMACEUTICAL COMPOSITIONS COMPRISING SAME AS INHIBITORS OF IKK ENZYME ACTIVITY | BRISTOL MYERS SQUIBB CO (US) | 2010-04-21 | — | — | EP | disclosed |
| EP-1888584-A1 | 1, 6 -DIHYDRO- 1,3, 5, 6-TETRAAZA-AS-INDACENE BASED TRICYCLIC COMPOUNDS AND PHARMACEUTICAL COMPOSITIONS COMPRISING SAME AS INHIBITORS OF IKK ENZYME ACTIVITY | Brystol-Myers Squibb Company (US) | 2008-02-20 | — | — | EP | disclosed |
| US-20060270654-A1 | 1,6-Dihydro-1,3,5,6-Tetraaza-as-indacene based tricyclic compounds and pharmaceutical compositions comprising same | BRISTOL-MYERS SQUIBB COMPANY | 2006-11-30 | — | — | US | disclosed |
| WO-2006122137-A1 | 1, 6 -DIHYDRO- 1,3, 5, 6-TETRAAZA-AS-INDACENE BASED TRICYCLIC COMPOUNDS AND PHARMACEUTICAL COMPOSITIONS COMPRISING SAME AS INHIBITORS OF IKK ENZYME ACTIVITY | BRISTOL-MYERS SQUIBB COMPANY (US) | 2006-11-16 | — | — | WO | disclosed |
Patent text — is the patent's own abstract consistent with the prediction?
For each of this compound's patents that has machine-readable text (6 of them — usually the abstract, not the full specification), we ask MedCPT which protein the text reads most about, and where the chemistry-predicted target lands among 4885 human targets. A high rank means the patent's own wording is consistent with the prediction — a weak, independent signal, not proof of activity.
| Patent | Title | Text reads most about | Predicted target · text-rank |
|---|---|---|---|
| US-20150011465-A1 | PEPTOID OLIGOMERS, PHARMACEUTICAL COMPOSITIONS AND METHODS OF USING THE SAME | NOD2, VIP, NOD1 | HDAC1 4268/4885HDAC2 4378/4885HDAC6 838/4885 |
| US-20160219880-A1 | PEPTOID OLIGOMERS, PHARMACEUTICAL COMPOSITIONS AND METHODS OF USING THE SAME | NOD2, VIP, NOD1 | HDAC1 4268/4885HDAC2 4378/4885HDAC6 838/4885 |
| US-20100210629-A1 | 1,6-DIHYDRO-1,3,5,6-TETRAAZA-AS-INDACENE BASED TRICYCLIC COMPOUNDS AND PHARMACEUTICAL COMPOSITIONS COMPRISING SAME | IL1R1, IDO1, TLR1 | HDAC1 387/4885HDAC2 1043/4885HDAC6 938/4885 |
| US-20060270654-A1 | 1,6-Dihydro-1,3,5,6-Tetraaza-as-indacene based tricyclic compounds and pharmaceutical compositions comprising same | IL1R1, IDO1, TLR1 | HDAC1 387/4885HDAC2 1043/4885HDAC6 938/4885 |
| US-20190055283-A1 | AZA-PEPTIDE ALDEHYDES AND KETONES | VIP, DNPEP, PEPD | HDAC1 68/4885HDAC2 278/4885HDAC6 104/4885 |
| US-20100222255-A1 | PEPTOID OLIGOMERS, PHARMACEUTICAL COMPOSITIONS AND METHODS OF USING THE SAME | NOD2, VIP, NOD1 | HDAC1 4268/4885HDAC2 4378/4885HDAC6 838/4885 |
“Text reads most about” is the patent abstract's nearest protein in MedCPT space (background-debiased). Only ~1.4% of patents have machine-readable text, so most compounds won't have this panel.